Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation

Fong et al. show that spliceosomal mutant leukemias are preferentially sensitive to inhibition of protein arginine methyltransferases (PRMTs), that RNA-binding proteins are enriched among substrates of PRMT5 and type I PRMTs, and that combined PRMT5 and type I PRMT inhibition synergistically kill these leukemia cells.

from Cancer Cell https://ift.tt/2OQiF3X